Ally Bridge Group’s Immunovant IMVT Stock Holding History

Ally Bridge Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-260,000	Closed	-$4.17M	–	33
2021 Q1	$4.17M	Buy	+260,000	New	+$6.86M	0.8%	29

Other funds holding IMVT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ally Bridge Group's IMVT Position: Q2 2021 in Review

Ally Bridge Group sold out of Immunovant (IMVT) in Q2 2021, closing a stake of 260,000 shares — an estimated $4.17M sold.

Ally Bridge Group first reported a position in IMVT in Q1 2021 and held it in 1 quarter. The position peaked at $4.17M in Q1 2021. 110 funds tracked by Wall St. Rank hold IMVT as of Q2 2021.

Ally Bridge Group reported no remaining Immunovant position as of Q2 2021 after selling out during the quarter.
Ally Bridge Group sold 260,000 Immunovant shares in Q2 2021, an estimated $4.17M.
Ally Bridge Group first reported a position in Immunovant in Q1 2021 and held it in 1 quarter.
Ally Bridge Group's Immunovant position peaked at $4.17M in Q1 2021.
110 funds tracked by Wall St. Rank held Immunovant as of Q2 2021.

Based on Ally Bridge Group's 13F filing for Q2 2021, filed 16 Aug 2021.